ArticleFrontiers in immunology2025
Identification of CTSC-driven progression in ESCC by single-cell sequencing and experimental validation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The progression of cancer cells is influenced by the tumor microenvironment (TME); however, the molecular mechanisms driving the progression of esophageal squamous cell carcinoma (ESCC) remain unclear. Therefore, we aimed to investigate the TME of ESCC and construct a risk signature based on apoptosis-related genes to identify prognosis-related genes in ESCC. Methods: We integrated a total of 92,714 cells from 18 samples across three single-cell datasets to analyze the differences in cellular landscapes between primary tumor tissues and adjacent normal tissues. Subsequently, univariate COX regression analysis was employed to construct an apoptosis-related prognostic risk model. The expression of key risk genes was elucidated using immunohistochemistry (IHC). Additionally, the effects of CTSC knockdown on ESCC cell behavior were validated through Results: We identified three malignant cell subtypes (Malig1, Malig2, and Malig4) associated with worse prognosis, which were enriched in apoptosis-related pathways. Pseudotime analysis revealed that the expression scores of apoptosis-related pathways increased along the inferred pseudotime, indicating that apoptosis plays a critical regulatory role in the differentiation of malignant epithelial cells. Furthermore, analysis of the TME demonstrated that immune cells and cancer-associated fibroblasts (CAFs) were significantly more abundant in tumor tissues compared to non-tumor tissues. Additionally, we identified eight apoptosis-related genes associated with prognosis, among which the expression of CTSC was closely correlated with resistance outcomes in patients receiving neoadjuvant immunotherapy. Conclusions: CTSC plays a crucial role in driving TME remodeling and the progression of drug resistance in ESCC, making it a potential target for clinical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.